AR and cancer: To validate our bioinformatics methods, which were very similar to those used in Pomerantz et al., we first reanalyzed the publicly available AR ChIP‐seq data from the Pomerantz et al. (2015) patient samples (normal = 7, tumor = 13; Gleason 3 + 3 to 5 + 5) and were able to recapitulate the robust segregation of cancer from normal samples via unsupervised hierarchical clustering (Fig. S2).